Compare KOD & OSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOD | OSW |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | Bahamas |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2018 | 2019 |
| Metric | KOD | OSW |
|---|---|---|
| Price | $41.34 | $26.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $35.43 | $27.00 |
| AVG Volume (30 Days) | 787.2K | ★ 891.1K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $961,001,000.00 |
| Revenue This Year | N/A | $7.49 |
| Revenue Next Year | N/A | $8.52 |
| P/E Ratio | ★ N/A | $122.81 |
| Revenue Growth | N/A | ★ 7.37 |
| 52 Week Low | $6.21 | $19.06 |
| 52 Week High | $47.84 | $29.25 |
| Indicator | KOD | OSW |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 49.63 |
| Support Level | $39.37 | $25.95 |
| Resistance Level | $46.72 | $27.06 |
| Average True Range (ATR) | 2.96 | 0.78 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 60.79 | 46.53 |
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.